Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients

Abstract Lenalidomide, bortezomib, and dexamethasone (RVd) have previously been established as standard-of-care induction therapy for newly diagnosed multiple myeloma (NDMM). More recently, randomized phase 3 data have demonstrated the benefit of the addition of daratumumab (Dara-RVd) to the RVd bac...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Nisha S. Joseph, Jonathan L. Kaufman, Vilas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Lawrence H. Boise, Sara M. DiCamillo, Danielle Roberts, Ajay K. Nooka, Sagar Lonial
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Nature Publishing Group 2024-09-01
Reeks:	Blood Cancer Journal
Online toegang:	https://doi.org/10.1038/s41408-024-01120-9
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!